(路透社消息)百健艾迪与Swedish Orphan Biovitrum，血液疾病药物Eloctate在一项治疗儿童下载应用领取微信红包的后期试验中有效。这款药物在治疗儿童下载应用领取微信红包A时能保持较低的出血率。
百健艾迪与Swedish Orphan Biovitrum还共同开发了另一款下载应用领取微信红包药物Alprolix，这款药物于上个月被FDA批准用于治疗下载应用领取微信红包B。下载应用领取微信红包B由因子IX缺乏引起。
(Reuters) - Biogen Idec Inc and Swedish Orphan Biovitrum said their experimental blood disorder drug was effective in treating children with hemophilia in a late-stage trial.
The drug, Eloctate, was able to maintain low bleeding rates in children with hemophilia A - a rare genetic disorder in which a person's blood does not clot properly due to missing or reduced levels of a protein called factor VIII.
The late-stage trial tested Eloctate in previously treated children under 12 years with severe hemophilia A.
The main goal of the study was to evaluate the frequency of antibody development that can interfere with the therapy and none were detected.
Eloctate is a long-acting hemophilia treatment that was given to patients as twice-weekly preventive injections.
Hemophilia drugs generally need to be infused every two or three days to prevent bleeding episodes.
Biogen and Swedish Orphan Biovitrum have also developed another hemophilia drug, Alprolix, that was approved by the U.S. Food and Drug Administration last month for treating hemophilia B. Hemophilia B is caused by the absence of the factor IX protein.
Biogen shares were up slightly at $300.92 in premarket trading. They closed at $300.68 on Wednesday on the Nasdaq.